ReviewThe Journal of biological chemistry2014
The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.
Review in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Newborn screening and biobanking for preventable genetic disorders in Mongolia: A developing country perspective.Regenerative therapy · 2026Review
- Airflow controlled droplet bioprinting enables high-throughput generation of iPSC-derived thymic organoids withBiofabrication · 2026Article
- The Promise of 3D Biomaterial Bioprinting for Wound-Healing and Skin Tissue Restoration.Life (Basel, Switzerland) · 2026Review
- Integrating living biomaterials into neuroelectronic systems.Biomedical engineering letters · 2026Review
- Chondrogenic Differentiation of Stem Cells for Cartilage Regeneration: Advances and Future Perspectives.Tissue engineering and regenerative medicine · 2026Review
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- Stem Cells in Regenerative Medicine: A Journey from Adult Stem Cells to Induced Pluripotent Cells.International journal of molecular sciences · 2025Review
- Clinical Applications of Corneal Cells Derived from Induced Pluripotent Stem Cells.Biomolecules · 2025Review
- Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies.Cell reports. Medicine · 2025Article
- Safety and Efficacy of Stem Cell Therapy in Ischemic Stroke: A Comprehensive Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Clinical translation of human iPSC technologies: advances, safety concerns, and future directions.Frontiers in cell and developmental biology · 2025Review
- Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques.Cell stem cell · 2024Article
- Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.International journal of molecular sciences · 2024Review
- Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation.Frontiers in immunology · 2024Review
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Comparing the Benefits and Drawbacks of Stem Cell Therapy Based on the Cell Origin or Manipulation Process: Addressing Immunogenicity.Immune network · 2023Review
- Neural stem cells for Parkinson's disease management: Challenges, nanobased support, and prospects.World journal of stem cells · 2023Review
- State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.American journal of physiology. Heart and circulatory physiology · 2022Review
- A Survey and Critical Evaluation of Isolation, Culture, and Cryopreservation Methods of Human Amniotic Epithelial Cells.Cell cycle (Georgetown, Tex.) · 2022Review
- Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize it will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.